Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.
2.

[Cytokines in bone diseases. Wnt signal and excessive bone formation].

Hosoi T.

Clin Calcium. 2010 Oct;20(10):1526-31. doi: CliCa101015261531. Review. Japanese.

PMID:
20890035
3.

[Regulation of bone metabolism by pathogenic mutations and polymorphism in the LRP5-Wnt signaling genes].

Urano T.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:95-100. Review. Japanese. No abstract available.

PMID:
18161089
4.

LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.

Levasseur R, Lacombe D, de Vernejoul MC.

Joint Bone Spine. 2005 May;72(3):207-14. Review.

PMID:
15850991
5.

Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.

Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG.

Bone. 2006 Oct;39(4):754-66. Epub 2006 May 26.

PMID:
16730481
6.

Genetic disorders of the LRP5-Wnt signalling pathway affecting the skeleton.

Koay MA, Brown MA.

Trends Mol Med. 2005 Mar;11(3):129-37. Review.

PMID:
15760771
7.

Wnt signaling: a key regulator of bone mass.

Baron R, Rawadi G, Roman-Roman S.

Curr Top Dev Biol. 2006;76:103-27. Review.

PMID:
17118265
8.

Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells.

Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM, Kassem M.

J Bone Miner Res. 2007 Nov;22(11):1720-31.

9.

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.

Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr.

Bone. 2008 Apr;42(4):669-80. doi: 10.1016/j.bone.2007.12.006. Epub 2007 Dec 27.

PMID:
18294945
10.

Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population.

Mencej-Bedrac S, Prezelj J, Kocjan T, Komadina R, Marc J.

Calcif Tissue Int. 2009 Dec;85(6):501-6. doi: 10.1007/s00223-009-9306-y. Epub 2009 Nov 7.

PMID:
19898734
11.

The Wnt signaling pathway and bone metabolism.

Johnson ML, Kamel MA.

Curr Opin Rheumatol. 2007 Jul;19(4):376-82. Review.

PMID:
17551370
12.

The A1330V polymorphism of the low-density lipoprotein receptor-related protein 5 gene (LRP5) associates with low peak bone mass in young healthy men.

Saarinen A, Välimäki VV, Välimäki MJ, Löyttyniemi E, Auro K, Uusen P, Kuris M, Lehesjoki AE, Mäkitie O.

Bone. 2007 Apr;40(4):1006-12. Epub 2007 Jan 12.

PMID:
17223614
13.

[Wnt-beta-catenin signaling in bone metabolism].

Urano T.

Clin Calcium. 2006 Jan;16(1):54-60. Review. Japanese.

PMID:
16397351
14.

LRP5 and Wnt signaling: a union made for bone.

Johnson ML, Harnish K, Nusse R, Van Hul W.

J Bone Miner Res. 2004 Nov;19(11):1749-57. Epub 2004 Aug 23. Review. No abstract available.

15.

Wnt signaling control of bone cell apoptosis.

Bodine PV.

Cell Res. 2008 Feb;18(2):248-53. doi: 10.1038/cr.2008.13. Review.

16.

Missense mutations in LRP5 are not a common cause of idiopathic osteoporosis in adult men.

Crabbe P, Balemans W, Willaert A, van Pottelbergh I, Cleiren E, Coucke PJ, Ai M, Goemaere S, van Hul W, de Paepe A, Kaufman JM.

J Bone Miner Res. 2005 Nov;20(11):1951-9. Epub 2005 Jul 11.

17.

Low-density lipoprotein receptor-related protein 5 polymorphisms are associated with bone mineral density in Greek postmenopausal women: an interaction with calcium intake.

Stathopoulou MG, Dedoussis GV, Trovas G, Katsalira A, Hammond N, Deloukas P, Lyritis GP.

J Am Diet Assoc. 2010 Jul;110(7):1078-83. doi: 10.1016/j.jada.2010.04.007. Erratum in: J Am Diet Assoc. 2010 Oct;110(10):1572.

PMID:
20630166
18.

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D.

J Biol Chem. 2005 May 20;280(20):19883-7. Epub 2005 Mar 18.

19.

The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.

Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, Van Hul W.

Calcif Tissue Int. 2008 Jun;82(6):445-53. doi: 10.1007/s00223-008-9130-9.

PMID:
18521528
20.

The high bone mass family--the role of Wnt/Lrp5 signaling in the regulation of bone mass.

Johnson ML.

J Musculoskelet Neuronal Interact. 2004 Jun;4(2):135-8. Review.

Supplemental Content

Support Center